# Neuroprotective Effects of Strength Training on Behavioral Deficit, Oxidative Damage, Astrogliosis, and Neuronal Death in a Bipolar Disorder Model

**Authors:** Luan Machado Maidana, Jozyê Milena da Silva Guerra, Adson Souza‐Pereira, Mustafa Munir Mustafa Dahleh, Douglas Buchmann Godinho, Marina Prigol, Luiz Fernando Freire Royes, Leonardo Magno Rambo

PMC · DOI: 10.1111/jnc.70392 · 2026-03-06

## TL;DR

Strength training protects the brain in a rat model of bipolar disorder by reducing oxidative stress, inflammation, and neuronal damage.

## Contribution

This study is the first to show that strength training has neuroprotective effects in a bipolar disorder model.

## Key findings

- Strength training prevented manic- and depressive-like behaviors and cognitive impairments in a BD rat model.
- Exercise reduced oxidative stress, neuroinflammation, and neuronal death induced by ouabain.
- Strength training restored antioxidant defenses and reduced glial reactivity and neuronal degeneration.

## Abstract

Bipolar disorder (BD) is associated with mood dysregulation and neurobiological abnormalities such as oxidative stress, neuroinflammation, and neurodegeneration. While physical exercise shows promise in mental health, the mechanistic effects of strength training in BD remain poorly understood. This study aimed to investigate the impact of an 8‐week strength training protocol on behavioral, oxidative, and cellular alterations in a validated rat model of BD induced by ouabain. Adult male Wistar rats were randomly assigned to sedentary or exercised groups. After the training period, animals underwent surgery for cannula implantation. Following recovery, they received either ouabain or artificial cerebrospinal fluid. Behavioral assessments were conducted during the manic‐ (Day 7) and depressive‐like (Day 14) phases, and tissue samples were collected on Day 18 post‐injection. Neurochemical assays and immunohistochemical analyses were performed in the cerebral cortex and hippocampus. Ouabain induced manic‐ and depressive‐like behaviors, cognitive impairments along with oxidative imbalance, increased NF‐κB activation, astrogliosis, and neuronal degeneration. Notably, prior strength training prevented these behavioral disturbances and significantly attenuated oxidative stress, neuroinflammation, and cell death. Physical exercise normalized antioxidant enzyme activities, reduced reactive species accumulation, prevented NF‐κB activation, and decreased GFAP and Fluoro Jade‐C labeling. Correlation analyses revealed significant associations among oxidative stress, inflammation, neurodegeneration, and cognitive impairment. These findings demonstrate, for the first time, that structured strength training exerts neuroprotective effects in a BD model by modulating redox homeostasis, inflammatory signaling, and neuronal integrity. Strength training emerges as a promising, low‐cost, and mechanistically grounded adjunctive strategy in BD management.

Schematic representation of the neuroprotective effects of strength training in an ouabain‐induced model of bipolar disorder. The intracerebroventricular injection of ouabain induces behavioral alterations (manic‐ and depressive‐like behaviors and cognitive deficits), increases oxidative stress (↑reactive species, ↓antioxidant defenses), promotes astrogliosis, and leads to neuronal death. In contrast, strength training attenuates these pathological changes, preventing behavioral deficits, restoring redox balance, reducing glial reactivity, and preserving neuronal integrity. Red elements represent ouabain‐induced effects, while green elements indicate effects of exercise. OUA, ouabain.

## Linked entities

- **Proteins:** NFKB1 (nuclear factor kappa B subunit 1), GFAP (glial fibrillary acidic protein)
- **Chemicals:** ouabain (PubChem CID 439501)
- **Diseases:** bipolar disorder (MONDO:0004985)

## Full-text entities

- **Genes:** Nos2 (nitric oxide synthase 2) [NCBI Gene 24599] {aka Nos2a, iNos}, Pik3cg (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma) [NCBI Gene 298947] {aka Pi3k}, Cat (catalase) [NCBI Gene 24248] {aka CS1, Cas1, Cat01, Catl, Cs-1}, Rps6kb1 (ribosomal protein S6 kinase B1) [NCBI Gene 83840] {aka p70 S6K-alpha}, Ephb1 (Eph receptor B1) [NCBI Gene 24338] {aka Ephb2, Erk, elk}, Gfap (glial fibrillary acidic protein) [NCBI Gene 24387], Ca1 (carbonic anhydrase 1) [NCBI Gene 310218] {aka CA-I, Car1}, Gsr (glutathione-disulfide reductase) [NCBI Gene 116686], Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56718] {aka Frap1, RAFT1}, Ca3 (carbonic anhydrase 3) [NCBI Gene 54232] {aka Car3}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, Hpgds (hematopoietic prostaglandin D synthase) [NCBI Gene 58962] {aka Ptgds2}, Creb1 (cAMP responsive element binding protein 1) [NCBI Gene 81646] {aka Creb}, Akt1 (AKT serine/threonine kinase 1) [NCBI Gene 24185] {aka Akt}, RBFOX3 (RNA binding fox-1 homolog 3) [NCBI Gene 146713] {aka FOX-3, FOX3, HRNBP3, NEUN}, Casp3 (caspase 3) [NCBI Gene 25402] {aka CPP32-beta, Lice, Yama}, Ptgs2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 29527] {aka COX-2, Cox2, PGHS-2, PHS II, Pghs2}
- **Diseases:** neuroinflammation (MESH:D000090862), schizophrenia (MESH:D012559), anxiety (MESH:D001007), RSD (MESH:D000303), Behavioral Deficit (MESH:D019958), behavioral alterations (MESH:D001523), neurotoxic (MESH:D020258), impaired respiratory chain activity (MESH:D028361), pain (MESH:D010146), aCSF (MESH:D002559), neurodegeneration (MESH:D019636), Inflammatory (MESH:D007249), Damage (MESH:D020263), distress (MESH:D012128), neuronal dysfunction (MESH:D009461), mood dysregulation (MESH:D019964), neuropsychiatric (MESH:C000631768), hypertrophy (MESH:D006984), hypoglycemia (MESH:D007003), Astrogliosis (MESH:D005911), neurobiological abnormalities (MESH:D000014), memory deficits (MESH:D008569), cognitive deficits (MESH:D003072), BD (MESH:D001714), DTNB (MESH:D008232), and depressive (MESH:D003866), Neuronal Death (MESH:D009410)
- **Chemicals:** 2',7'-dichlorodihydrofluorescein diacetate (MESH:C110400), polyacrylamide (MESH:C016679), epinephrine (MESH:D004837), Triton X-100 (MESH:D017830), xylazine (MESH:D014991), potassium phosphate (MESH:C013216), nitrogen (MESH:D009584), xylene (MESH:D014992), phosphate (MESH:D010710), NaCl (MESH:D012965), sodium hydroxide (MESH:D012972), ethanol (MESH:D000431), polyethylene (MESH:D020959), SDS (MESH:D012967), 5,5'-dithiobis-(2-nitrobenzoic acid) (MESH:D004228), acetic acid (MESH:D019342), chlorhexidine (MESH:D002710), 4-HNE (MESH:C027576), N-methyl-D-aspartate (MESH:D016202), Ponceau S (MESH:C032756), dichlorofluorescein (MESH:C037631), 3-NT (MESH:C002744), DCFH-DA (MESH:C029569), sodium azide (MESH:D019810), water (MESH:D014867), potassium permanganate (MESH:D011196), FJC (MESH:C534582), trichloroacetic acid (MESH:D014238), GSSG (MESH:D019803), NADP+ (MESH:D009249), dipyrone (MESH:D004177), Thiol (MESH:D013438), O2- (MESH:D013481), NPSH (-), H2O2 (MESH:D006861), calcium (MESH:D002118), 1-chloro-2,4-dinitrobenzene (MESH:D004137), ROS (MESH:D017382), dextrose (MESH:D005947), 4',6-Diamidino-2-Phenylindole (MESH:C007293), heparin (MESH:D006493), PBS (MESH:D007854), TBS-T (MESH:C027647), Tween-20 (MESH:D011136), acepromazine (MESH:D000075), sodium carbonate (MESH:C005686), PFA (MESH:C003043), lipids (MESH:D008055), sucrose (MESH:D013395), OUA (MESH:D010042), GSH (MESH:D005978), BCA (MESH:C047117), ATP (MESH:D000255)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]

## Figures

14 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12964509/full.md

---
Source: https://tomesphere.com/paper/PMC12964509